Phase 2 Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to understand and sign a consent form, and to follow the study schedule and requirements.
• People who have been diagnosed with melanoma or another advanced solid tumour, confirmed by tissue testing.
• People who have already received at least one systemic (whole-body) cancer treatment, whose cancer has continued to grow or spread during or after their most recent treatment, and for whom no further standard treatment is available or who cannot tolerate standard treatment.
• People who have at least one tumour that can be measured using standard imaging guidelines (RECIST v1.1).
• People who are generally able to carry out daily activities with little or no limitation (ECOG performance status of 0 or 1 — confirm with trial site if unsure what this means).
• People with a life expectancy of at least 3 months.
• People whose heart, liver, kidneys, and other organs are functioning adequately (specific thresholds to be confirmed with the trial site).
• Women who could become pregnant must agree to use two effective methods of contraception during treatment and for at least 12 weeks after the last dose.
• Women who could become pregnant must have a negative blood pregnancy test within 7 days before the first dose.
• Male participants must agree to use a latex condom during treatment and for at least 12 weeks after the last dose, even if they have had a vasectomy.
• All participants must agree not to donate sperm or eggs during treatment and for at least 12 weeks after the last dose.
• A tumour tissue sample must be available at the time of screening.

Who may not be able to join:

• People who have previously been treated with a therapy that targets the same biological target as the trial drug (confirm specific target with trial site).
• People who have cancer that has spread to the brain or central nervous system.
• People with an ongoing or long-term skin condition that requires systemic (whole-body) treatment.
• People with a history of Stevens-Johnson syndrome or toxic epidermal necrolysis (serious skin reactions).
• People still experiencing side effects above a mild level (Grade 1) from previous cancer treatments.
• People who have received systemic cancer treatment within 21 days (or within five half-lives of that treatment, whichever is shorter) before the first dose.
• People who have had major surgery within 28 days before the first dose, or who have not yet recovered from a recent surgery.
• People with serious heart conditions, such as a recent heart attack, heart failure, uncontrolled high blood pressure, or uncontrolled irregular heartbeat.
• People who have had a blood clot, stroke, mini-stroke (TIA), deep vein thrombosis, or pulmonary embolism within the six months before the first dose.
• People with an active serious infection, or a known diagnosis of hepatitis B, hepatitis C, or HIV.
• People who have received a live vaccine within 28 days before the first dose.

Important: Always verify eligibility with the trial site directly before applying.